Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

COVID-19 Crisis: An Update on the Disruption of Clinical trials

Version 1 : Received: 24 May 2020 / Approved: 25 May 2020 / Online: 25 May 2020 (11:17:56 CEST)

How to cite: Kumar, V. COVID-19 Crisis: An Update on the Disruption of Clinical trials. Preprints 2020, 2020050411. Kumar, V. COVID-19 Crisis: An Update on the Disruption of Clinical trials. Preprints 2020, 2020050411.


COVID-19 is causing major turmoil around the globe, and the clinical trial industry is likely to face unprecedented challenges to health and business sectors. In an effort to find a suitable treatment and prevention options for COVID-19, several COVID-19 clinical trials are being planned and initiated, while a large number of clinical trials for non- COVID-19 indications are suffering delays. With over more than 1000 trials being disrupted and more trials being added to this category daily, there is a direct impact on trial site activation and patient enrolment. This analysis deals with the specific impacts of the COVID-19 pandemic on the clinical trial and pharmaceutical industry. The objective of this study is to provide an updated information of the disrupted clinical trials and its impact on various therapeutic areas and different drugs. Among the severely affected clinical trials, oncology and CNS trials are the hardest hit therapy areas.This article will certainly emphasize the need for advanced and innovative approaches to maintain the health of the clinical trial ecosystem by continuing the existing trials and the start of the new studies. We have to take and follow necessary actions to guarantee that the initiatives will not be locked during the COVID-19 pandemic, both for the treatment of patients and for the researchers to conduct decision-relevant clinical trials.


COVID-19; Clinical Trials; disruption; non-COVID-19 clinical trials; drugs; therapeutic area


Medicine and Pharmacology, Epidemiology and Infectious Diseases

Comments (1)

Comment 1
Received: 28 May 2020
Commenter: Prof. Anna Bonaconsa
The commenter has declared there is no conflict of interests.
Comment: The article's topic of discussion is good but the author should give more details. The data representation has a lot of scope for improvement. I found a few of the analyses done wrongly. Please recheck your analyses and the usage of the English language for explicitness.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.